COX-2 inhibitor actions

FDA's drug safety committee will review the agency's actions regarding the safety of COX-2 inhibitors on Feb. 10. Two selective COX-2 non-steroidal anti-inflammatory drugs have been pulled from the market, Merck's Vioxx and Pfizer's Bextra. Pfizer's Celebrex remains on the market (1"The Pink Sheet" Dec. 19, 2005, p. 18). The committee will also receive updates on the Drug Safety Oversight Board and risk management programs for isotretinoin products. The meeting will take place at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m...